Biotech | December 22, 2021
Piramal Pharma takes a minority stake in Yapan Bio
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
The company will manufacture a cancer immunotherapy product from 2022
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
The Indian medical devices industry has been in focus since the pandemic. From US $ 11 billion in 2020 it is expected to touch US $ 50 billion by 2025. Mehernosh Daruwalla, Founder and MD, Lotus Surgicals shares a perspective with Thomas C Thottathil on the opportunities in this sector
Officials from ACG signed the MoU with the Maharashtra government for the Rs 600 crore investment in the backward region of Marathwada
The new facility will provide an important boost to vaccine capacity in Africa
Acute therapies continue to report strong growth compared to chronic ones.
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
This new lyophilizer is equipped with systems to best protect high value Active Pharmaceutical Ingredients (APIs) and doubles the lyophilization capacity at the site
Subscribe To Our Newsletter & Stay Updated
